Navigation Links
ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
Date:9/28/2008

LEUVEN, Belgium, September 29 /PRNewswire-FirstCall/ --

- Results Presented at World Stroke Congress in Vienna

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on novel therapies for eye disease, vascular disease and cancer, announces positive results from its MITI IV Phase II trial to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to acute stroke patients. The trial showed that microplasmin was generally well tolerated and also provided some interesting preliminary efficacy data. The overall results of the study were presented by Dr. Vincent Thijs on September 27 at a Late-Breaking Clinical Trial session at the World Stroke Congress.

The MITI IV (Microplasmin In Treatment of Ischemic stroke - IntraVenous) trial was a Phase II, multicentre, randomized, double-blinded, placebo-controlled, ascending-dose clinical trial evaluating the safety and preliminary efficacy of the intravenous administration of microplasmin in 40 patients, 4 to 12 hours after onset of acute ischemic stroke. The trial investigated three dose regimens of microplasmin (2, 3, and 4 mg/kg total dose) compared to placebo. Clinical outcomes were assessed at seven days and 30 days post-treatment, and at each of these visits neurological assessments were performed.

The study found that microplasmin was generally well tolerated with no evidence of increased bleeding risk; there were no systemic bleeding events reported and there was no evidence of increased rate of bleeding in general, in those patients that had been treated with microplasmin compared to those treated with placebo.

In addition, the study provided some interesting preliminary efficacy results. Approximately 25% of patients treated with microplasmin had reperfusion (restoration of blood flow) within eight hours of being treated, this compares with 10% of placebo-treated patients. Moreover, of the patients who had more severe va
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
3. Clinton Global Initiative Announces BDs Commitment to Biamba Marie Mutombo Hospital
4. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
5. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
6. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
7. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
8. Phosphagenics Announces Initiation of Phase 1 Clinical Trial in Humans for Its Transdermal Lidocaine
9. Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera
10. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
11. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) Needle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Fla. , July 11, 2014  Rock Creek ... biotechnology company, today announced that the Food and Drug ... will provide comments on RCP,s Investigational New Drug ("IND") ... clinical trial in the US. Dr. ... agency,s review and comments on our IND. When we ...
(Date:7/11/2014)... Australia , July 11, 2014  Australian drug ... announced that it has raised A$19.3 million via a ... Europe , the U.S., Asia ... A$3 million from a share purchase plan (SPP) to ... million will be made in two tranches. ...
(Date:7/11/2014)... Show organisers report ... Expo 2014 were a brand new audience ... London , plus a 10% increase ...      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ) ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
(Date:7/14/2014)... 13, 2014 (HealthDay News) -- Eye tests could be ... Alzheimer,s disease, two new studies suggest. In one ... certain eye test found a significant association between levels ... and levels of the plaques in the brain. Beta-amyloid ... This type of eye test could be used ...
(Date:7/14/2014)... MONDAY, July 14, 2014 (HealthDay News) -- Being physically ... risk for Alzheimer,s disease and other types of dementia, ... our studies, we found that physical exercise at various ... Dr. Yonas Geda from the Mayo Clinic, said in ... results, but they are not yet conclusive. More research ...
(Date:7/14/2014)... HealthDay Reporter MONDAY, July 14, 2014 ... multiple health issues, but dementia isn,t one of them, according ... even delay dementia, the researchers found. "For those who ... with a later age of developing full-blown dementia compared to ... Woodruff, an assistant professor of neurology at the ...
(Date:7/14/2014)... 14, 2014 Follow ... liquid chromatography or UPLC is a new ... chromatography that involves the use of extremely ... separate chromatographic compounds. This highly sensitive qualitative ... and analysis of chromatography samples. UPLC functions ...
(Date:7/14/2014)... Clara, California (PRWEB) July 14, 2014 ... America for the 6th Annual 5K run and one-mile ... America, winds through the park attractions, and finishes inside ... event has raised over $150,000 for the Mission City ... throughout Santa Clara County. , Seasoned athletes, part-time ...
Breaking Medicine News(10 mins):Health News:Eye Tests Might Help ID Alzheimer's, Studies Suggest 2Health News:Staying Active May Help Prevent Dementia 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3Health News:Need for Faster Sample Analysis Drives Demand for UPLC, According to New Trend Report Published by Global Industry Analysts, Inc. 2
... on its services for individuals living with autism, and sharing the results ... the services and supports that families living with autism desperately need. ... ... shining the spotlight on its services for individuals living with autism, and ...
... the Family" with Allen Cardoza , Los Angeles, ... ANGELES, April 2 Our special guest this week ... successful private practice. Shelly has been a coach and ... corporate organizations as a Doctor of Psychology and a ...
... how a small hospital improved charge capture performance, ... using Craneware,s Bill AnalyzerATLANTA, April 2 Craneware, ... of financial performance solutions, announced today it will ... at the annual conference of the Healthcare Information ...
... The following is a statement from Jeff Levi, PhD, ... to the release of the new report Beyond Health ... Wood Johnson Foundation Commission to Build a Healthier America:"Every American ... or she can be. And every community should be ...
... Take Place on May 2; ... on May 9 LOS ANGELES, April 2 Revlon (NYSE: REV ... Jennifer Connelly and Jessica Alba along with NBC late night host ... in New York taking place on Saturday, May 2, 2009 , while ...
... with the glitazone class of diabetes drugs leads to ... edema (DME)a common complication that can lead to vision ... the American Journal of Ophthalmology ( http://www.elsevier.com/locate/ajo ... about 170,000 patients with diabetes, Drs. Donald S. Fong ...
Cached Medicine News:Health News:Easter Seals Celebrates World Autism Awareness Day, Hosting Series of Community Forums to Identify Needed Services and Supports for Families 2Health News:Easter Seals Celebrates World Autism Awareness Day, Hosting Series of Community Forums to Identify Needed Services and Supports for Families 3Health News:Easter Seals Celebrates World Autism Awareness Day, Hosting Series of Community Forums to Identify Needed Services and Supports for Families 4Health News:Easter Seals Celebrates World Autism Awareness Day, Hosting Series of Community Forums to Identify Needed Services and Supports for Families 5Health News:Craneware and St. Joseph to Present Revenue Enhancement Success Story at HIMSS 2Health News:Trust for America's Health Supports Recommendations from Robert Wood Johnson Foundation Commission to Build a Healthier America 2Health News:Trust for America's Health Supports Recommendations from Robert Wood Johnson Foundation Commission to Build a Healthier America 3Health News:Jessica Alba, Christina Applegate, Jennifer Connelly, Miley Cyrus & Jimmy Fallon on Board to Host Entertainment Industry Foundation's 2009 Revlon Run/Walk 2Health News:Jessica Alba, Christina Applegate, Jennifer Connelly, Miley Cyrus & Jimmy Fallon on Board to Host Entertainment Industry Foundation's 2009 Revlon Run/Walk 3Health News:Jessica Alba, Christina Applegate, Jennifer Connelly, Miley Cyrus & Jimmy Fallon on Board to Host Entertainment Industry Foundation's 2009 Revlon Run/Walk 4Health News:Diabetes drug class linked to vision-threatening complication 2
... a low osmolar ionic dimer. Each ... meglumine, 196 mg of ioxaglate sodium ... disodium as a stabilizer. The solution ... each milliliter and provides 32% (320 ...
... IMAGOPAQUE is a non-ionic monomeric contrast ... in adults and children. After a decade ... 3.5 million examinations, IMAGOPAQUE has proven to ... effort in hundreds of radiology departments.Results from ...
... is a liver-specific contrast agent approved for ... Its introduction expands the Amersham Health portfolio ... injected intravenously, TESLASCAN aids in the detection, ... Imaging can begin within minutes of injection, ...
... a new Contrast Agent for ... of stabilized SF6 microbubbles. The ... between 1 and 10 m, ... 2 and 5 x 108 ...
Medicine Products: